Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Debt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on Invested CapitalReturn on Sales

Dr Reddys Laboratories (RDY) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Dr Reddys Laboratories (RDY) over the last 17 years, with Q4 2025 value amounting to 16.32%.

  • Dr Reddys Laboratories' EBITDA Margin rose 187400.0% to 16.32% in Q4 2025 from the same period last year, while for Dec 2025 it was 12.7%, marking a year-over-year increase of 121100.0%. This contributed to the annual value of 22.09% for FY2025, which is 223300.0% up from last year.
  • Per Dr Reddys Laboratories' latest filing, its EBITDA Margin stood at 16.32% for Q4 2025, which was up 187400.0% from 20.75% recorded in Q1 2025.
  • Dr Reddys Laboratories' 5-year EBITDA Margin high stood at 26.26% for Q2 2023, and its period low was 2.42% during Q4 2024.
  • For the 5-year period, Dr Reddys Laboratories' EBITDA Margin averaged around 15.37%, with its median value being 19.66% (2022).
  • In the last 5 years, Dr Reddys Laboratories' EBITDA Margin crashed by -269300bps in 2024 and then surged by 215300bps in 2025.
  • Dr Reddys Laboratories' EBITDA Margin (Quarter) stood at 2.76% in 2021, then skyrocketed by 612bps to 19.66% in 2022, then tumbled by -93bps to 1.37% in 2023, then tumbled by -276bps to 2.42% in 2024, then surged by 774bps to 16.32% in 2025.
  • Its EBITDA Margin was 16.32% in Q4 2025, compared to 20.75% in Q1 2025 and 2.42% in Q4 2024.